LEO LABORATORIES LIMITED

🇮🇪Ireland
Ownership
-
Employees
-
Market Cap
-
Website

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-10-15
Last Posted Date
2019-02-28
Lead Sponsor
LEO Pharma
Target Recruit Count
59
Registration Number
NCT02575950
Locations
🇺🇸

Torrance Clinical Research Institute Inc., Lomita, California, United States

LEO 124249 Ointment in the Treatment of Alopecia Areata

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-09-28
Last Posted Date
2019-04-16
Lead Sponsor
LEO Pharma
Target Recruit Count
40
Registration Number
NCT02561585
Locations
🇺🇸

The Icahn School of Medicine, Mount Sinai Hospital, New York, New York, United States

🇺🇸

Northwestern University, Evanston, Illinois, United States

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-09-15
Last Posted Date
2018-12-26
Lead Sponsor
LEO Pharma
Target Recruit Count
391
Registration Number
NCT02549352
Locations
🇩🇪

Klinik für Dermatologie & Allergologie Klinikum Vest GmbH, Recklinghausen, Germany

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-09-15
Last Posted Date
2018-12-05
Lead Sponsor
LEO Pharma
Target Recruit Count
383
Registration Number
NCT02549339
Locations
🇺🇸

Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-09-11
Last Posted Date
2018-12-26
Lead Sponsor
LEO Pharma
Target Recruit Count
437
Registration Number
NCT02547233
Locations
🇺🇸

Altman Dermatology Associates, Arlington Heights, Illinois, United States

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-09-11
Last Posted Date
2018-12-26
Lead Sponsor
LEO Pharma
Target Recruit Count
373
Registration Number
NCT02547363
Locations
🇺🇸

Long Island Skin Cancer & Dermatologic Surgery, Smithtown, New York, United States

Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population

First Posted Date
2015-08-27
Last Posted Date
2018-12-20
Lead Sponsor
LEO Pharma
Target Recruit Count
951
Registration Number
NCT02533973
Locations
🇨🇳

The Second Affiliated hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris

First Posted Date
2015-08-07
Last Posted Date
2024-08-29
Lead Sponsor
LEO Pharma
Target Recruit Count
35
Registration Number
NCT02518048
Locations
🇫🇷

Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Nice, France

LEO 32731 - A Phase I Study in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-08-04
Last Posted Date
2017-05-03
Lead Sponsor
LEO Pharma
Target Recruit Count
27
Registration Number
NCT02514694
Locations
🇬🇧

Covance CRU, Leeds, United Kingdom

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

First Posted Date
2015-07-14
Last Posted Date
2017-05-03
Lead Sponsor
LEO Pharma
Target Recruit Count
30
Registration Number
NCT02496546
Locations
🇩🇪

Proinnovera GmbH, Center of Dermatology Excellence, Münster, Germany

© Copyright 2024. All Rights Reserved by MedPath